Corante

In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

Corante New York

« After 156 years, it's finally time to go public | Main | First Friendster, Now Elfster »

December 18, 2004

Tarceva takes on Iressa and wins

Email This Entry

Posted by Dominic Basulto

Shares of Long Island-based OSI Pharmaceuticals spiked by nearly 50% in early Friday trading on news that Iressa, a rival lung cancer drug from AstraZeneca, did not prolong patients' lives in a late-stage trial. As described earlier ("What happened to Long Island's biotech superstar?"), OSI Pharmaceuticals has been the subject of intense Wall Street speculation after receiving FDA approval for its Tarceva cancer drug in mid-November. Until the AstraZeneca announcement, many analysts had been skeptical that Tarceva would perform better than Iressa. Shares of OSI are now trading around the $70 mark.

Comments (0) + TrackBacks (0) | Category: Biotech


TrackBack URL:
http://www.corante.com/cgi-bin/mt/external.cgi/30455


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
East Village bar up for sale on eBay
Eliot Spitzer takes on the national cinema chains
California winemakers to sell wine to New Yorkers via the Internet
A blogger could become "Media Person of the Year"
A la carte cable TV pricing
NYSIA Incubator launch party tonight
Why the mathematics of congestion pricing don't work
Enjoy the holiday shopping bargains at Century 21 while you can